Skip to content

Clinical Efficacy and Safety of Fractional Carbon Dioxide Laser and Mini-Punch Excision in the Treatment of Linear White Scars: A Prospective Randomized Parallel-Controlled Study

Clinical Efficacy and Safety of Fractional Carbon Dioxide Laser and Mini-Punch Excision in the Treatment of Linear White Scars: A Prospective Randomized Parallel-Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107083
Enrollment
Unknown
Registered
2025-08-04
Start date
2025-08-04
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scar

Interventions

A:Treatment is performed using the CO? fractional laser in DeepFX mode. After the procedure, a cold compress is applied topically, followed by routine sun protection care. The treatment is administere
B:Based on the size and thickness of the scar, a circular punch of appropriate diameter (0.4–0.8 mm) is selected. After the skin is stretched taut, the punch is positioned perpendicular to the scar su

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Age between 18 and 65 years;(2)Presence of a linear scar =2 cm in length located on the face, trunk, or limbs, persisting for more than 6 months, with a willingness to improve the scar through treatment.

Exclusion criteria

Exclusion criteria: (1)Underwent invasive treatments such as ablative laser, punch excision, or injections within the past 6 months; (2)Scars currently in the proliferative phase; (3)Tendency toward dysphagia or dyspnea, or diagnosed with peripheral motor neuropathy; (4)Currently taking corticosteroids, anticoagulants, or any drugs/foods that may cause photosensitivity, including isotretinoin, or experiencing prolonged sun exposure; (5)Suffering from active infections, immunosuppressive conditions, coagulation disorders, or other hematologic diseases; (6)Diagnosed with neurological or psychiatric disorders; (7)Deemed unsuitable for participation by the investigator.

Design outcomes

Primary

MeasureTime frame
Change in total POSAS 3.0 score relative to baseline;

Secondary

MeasureTime frame
Change in total POSAS 3.0 score relative to baseline;Change in total mVSS score relative to baseline;

Countries

China

Contacts

Public ContactRongxin Ren

Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences

13811497743@163.com+86 132 4133 4914

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026